Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 5/2019

15.03.2019 | Original Article

Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA

verfasst von: Patrick Mayr, Bruno Märkl, Abbas Agaimy, Bernadette Kriening, Sebastian Dintner, Gerhard Schenkirsch, Regine Schneider-Stock

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastrointestinal stromal tumors (GISTs) are the most common soft tissue tumors of the GI tract. Studies have been published reporting additional neoplasms in GIST patients. This study aimed to evaluate possible associations of mutation type, morphology, and clinical aspects of GISTs.

Methods

All cases of GIST were identified from our pathology files. Coding exons of KIT and PDGFRA in GISTs with additional malignancies were sequenced.

Results

A total of 70 of 188 (37%) retrieved patients with confirmed diagnosis of GIST showed at least one additional malignant neoplasm. Fifty of these GISTs were located in the stomach (71%), 8 in the small intestine (11%), 5 in the colon/rectum (7%), and 7 cases (6.2%) were of undetermined sites of origin. The distribution of identified mutations was similar to that described in GISTs without secondary malignancies. A total of 37 of 57 cases (65%) showed mutations in the KIT gene exon 11, 3 (5%) cases in exon 9, and 1 (2%) case in exon 13. Nine tumors (16%) had mutations of the PDGFRA gene. KIT and PDGFRA wild-type status were found in seven cases (12%). Most of the secondary neoplasms were located within the GI tract (34%), in the urogenital system (24%), or the breast/female genital tract (20%).

Conclusion

This study confirms the high rate of additional malignant tumors in GIST patients. GIST features in these cases are very similar to those with sole GIST.
Literatur
1.
Zurück zum Zitat Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M (2006) Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 23:120–129CrossRefPubMed Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M (2006) Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 23:120–129CrossRefPubMed
2.
Zurück zum Zitat Aghdassi A, Christoph A, Dombrowski F, Döring P, Barth C, Christoph J, Lerch MM, Simon P (2018) Gastrointestinal stromal tumors: clinical symptoms, location, metastasis formation, and associated malignancies in a single center retrospective study. Dig Dis 36:337–345CrossRefPubMed Aghdassi A, Christoph A, Dombrowski F, Döring P, Barth C, Christoph J, Lerch MM, Simon P (2018) Gastrointestinal stromal tumors: clinical symptoms, location, metastasis formation, and associated malignancies in a single center retrospective study. Dig Dis 36:337–345CrossRefPubMed
3.
Zurück zum Zitat Amankwah EK, Conley AP, Reed DR (2013) Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 5:147–162PubMedPubMedCentral Amankwah EK, Conley AP, Reed DR (2013) Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 5:147–162PubMedPubMedCentral
4.
Zurück zum Zitat Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11:865–878CrossRefPubMed Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11:865–878CrossRefPubMed
5.
Zurück zum Zitat Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M (2012) A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol 23:1335–1340CrossRefPubMed Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M (2012) A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol 23:1335–1340CrossRefPubMed
6.
Zurück zum Zitat Fernández JA, Olivares V, Gómez-Ruiz AJ et al (2018) Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification. Clin Transl Oncol. https://doi.org/10.1007/s12094-018-1966-5 Fernández JA, Olivares V, Gómez-Ruiz AJ et al (2018) Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification. Clin Transl Oncol. https://​doi.​org/​10.​1007/​s12094-018-1966-5
7.
Zurück zum Zitat Goncalves R, Linhares E, Albagli R et al (2010) Occurrence of other tumors in patients with GIST. Surg Oncol 19:e140–e143CrossRefPubMed Goncalves R, Linhares E, Albagli R et al (2010) Occurrence of other tumors in patients with GIST. Surg Oncol 19:e140–e143CrossRefPubMed
8.
Zurück zum Zitat Hechtman JF, Dematteo R, Nafa K et al (2015) Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): a clinicopathologic study of 260 patients with molecular analysis and review of the literature. Ann Surg Oncol 22:2633–2639CrossRefPubMedPubMedCentral Hechtman JF, Dematteo R, Nafa K et al (2015) Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): a clinicopathologic study of 260 patients with molecular analysis and review of the literature. Ann Surg Oncol 22:2633–2639CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed
10.
Zurück zum Zitat Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P (2014) Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 120:2325–2333CrossRefPubMedPubMedCentral Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P (2014) Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 120:2325–2333CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kramer K, Wolf S, Mayer B, Schmidt SA, Agaimy A, Henne-Bruns D, Knippschild U, Schwab M, Schmieder M (2015) Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia 17:134–140CrossRefPubMedPubMedCentral Kramer K, Wolf S, Mayer B, Schmidt SA, Agaimy A, Henne-Bruns D, Knippschild U, Schwab M, Schmieder M (2015) Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia 17:134–140CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mendonca SJ, Sanchez A, Blum KA, Ghanaat M, Kashan MY, Benfante N, Russo P, Coleman JA, Crago AM, Hakimi AA (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716–1720CrossRefPubMedPubMedCentral Mendonca SJ, Sanchez A, Blum KA, Ghanaat M, Kashan MY, Benfante N, Russo P, Coleman JA, Crago AM, Hakimi AA (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716–1720CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130:1466–1478PubMed Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130:1466–1478PubMed
14.
Zurück zum Zitat Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68CrossRefPubMed Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68CrossRefPubMed
15.
Zurück zum Zitat Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776CrossRefPubMed Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776CrossRefPubMed
16.
Zurück zum Zitat Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK (2015) Increased risk of additional cancers among patients with gastrointestinal stromal tumors: a population-based study. Cancer 121:2960–2967CrossRefPubMedPubMedCentral Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK (2015) Increased risk of additional cancers among patients with gastrointestinal stromal tumors: a population-based study. Cancer 121:2960–2967CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103:821–829CrossRefPubMed Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103:821–829CrossRefPubMed
18.
Zurück zum Zitat Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC (2010) Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 21:2107–2111CrossRefPubMedPubMedCentral Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC (2010) Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 21:2107–2111CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Rodriquenz MG, Rossi S, Ricci R, Martini M, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D’Argento E, Strippoli A, Barone C, Cassano A (2016) Gastrointestinal stromal tumors (GISTs) and second malignancies: a novel “sentinel tumor”? A monoinstitutional, STROBE-compliant observational analysis. Medicine (Baltimore) 95:e4718CrossRef Rodriquenz MG, Rossi S, Ricci R, Martini M, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D’Argento E, Strippoli A, Barone C, Cassano A (2016) Gastrointestinal stromal tumors (GISTs) and second malignancies: a novel “sentinel tumor”? A monoinstitutional, STROBE-compliant observational analysis. Medicine (Baltimore) 95:e4718CrossRef
20.
Zurück zum Zitat Rubio-Casadevall J, Borras JL, Carmona-Garcia MC et al (2015) Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World J Surg Oncol 13:47CrossRefPubMedPubMedCentral Rubio-Casadevall J, Borras JL, Carmona-Garcia MC et al (2015) Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World J Surg Oncol 13:47CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Smith MJ, Smith HG, Mahar AL, Law C, Ko YJ (2016) The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors. Int J Cancer 139:1744–1751CrossRefPubMed Smith MJ, Smith HG, Mahar AL, Law C, Ko YJ (2016) The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors. Int J Cancer 139:1744–1751CrossRefPubMed
22.
Zurück zum Zitat Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100:162–168CrossRefPubMed Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100:162–168CrossRefPubMed
23.
Zurück zum Zitat Vassos N, Agaimy A, Hohenberger W, Croner RS (2014) Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: prognostic implications. Int J Surg 12:371–377CrossRefPubMed Vassos N, Agaimy A, Hohenberger W, Croner RS (2014) Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: prognostic implications. Int J Surg 12:371–377CrossRefPubMed
Metadaten
Titel
Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA
verfasst von
Patrick Mayr
Bruno Märkl
Abbas Agaimy
Bernadette Kriening
Sebastian Dintner
Gerhard Schenkirsch
Regine Schneider-Stock
Publikationsdatum
15.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 5/2019
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-019-01773-2

Weitere Artikel der Ausgabe 5/2019

Langenbeck's Archives of Surgery 5/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.